Yes I think they will partner the indications separately ....and actually it would be an amazing extra boost in value, having AD and Epilepsy both as optimized combo drugs, so they do not compete against any other drug off label, or each other.. Also with Epilepsy, I am wondering if they might have three separate drugs....since they had three combos that showed strong synergy...and since epilepsy is very complicated with many patients differing from one another, the combo that works best for a particular patient may be different from patient to patient...So this also begs the question, would they run three separate Epilepsy trials concurrent ...I think so, and likely with the same trial design...
If you think about all this is becomes evident why they retained an in house patent attorney...
News 
Market Data 
Discover 
